Correlation between ERK1 and STAT3 expression and chemoresistance in patients with conventional osteosarcoma-Reference-Cited by-同舟云学术

Correlation between ERK1 and STAT3 expression and chemoresistance in patients with conventional osteosarcoma

Published:2014-08-20 Issue:1 Volume:14 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Salas Sébastien,Jiguet-Jiglaire Carine,Campion Loic,Bartoli Catherine,Frassineti Frédéric,Deville Jean-Laurent,Maues De Paula André,Forest Fabien,Jézéquel Pascal,Gentet Jean-Claude,Bouvier Corinne

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/1471-2407-14-606.pdf

Reference39 articles.

1. Krailo M, Ertel I, Makley J, Fryer CJ, Baum E, Weetman R, Yunis E, Barnes L, Bleyer WA, Hammond GD: A randomized study comparing high-dose methotrexate with moderate-dose methotrexate as components of adjuvant chemotherapy in childhood nonmetastatic osteosarcoma: a report from the Childrens Cancer Study Group. Med Pediatr Oncol. 1987, 15 (2): 69-77.

2. Souhami RL, Craft AW, Van der Eijken JW, Nooij M, Spooner D, Bramwell VH, Wierzbicki R, Malcolm AJ, Kirkpatrick A, Uscinska BM, Van Glabbeke M, Machin D: Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet. 1997, 350 (9082): 911-917.

3. Bacci G, Picci P, Ruggieri P, Mercuri M, Avella M, Capanna R, Brach Del Prever A, Mancini A, Gherlinzoni F, Padovani G: Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer. 1990, 65 (11): 2539-2553.

4. Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, Marcove RC, Lane JM, Mehta B, Urban C: Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982, 49 (6): 1221-1230.

5. Rosen G, Marcove RC, Huvos AG, Caparros BI, Lane JM, Nirenberg A, Cacavio A, Groshen S: Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol. 1983, 106 (Suppl): 55-67.

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and experimental verification of novel angiogenesis related prognostic model and immune infiltration characterization in osteosarcoma;Discover Oncology;2024-09-05

2. Overexpression of miR-506-3p reversed doxorubicin resistance in drug-resistant osteosarcoma cells;Frontiers in Pharmacology;2024-02-14

3. Cold plasma and inhibition of STAT3 selectively target tumorigenicity in osteosarcoma;Redox Biology;2023-06

4. A Systematic Review of the Heterogenous Gene Expression Patterns Associated with Multidrug Chemoresistance in Conventional Osteosarcoma;Genes;2023-03-30

5. Fluoxetine Inhibits STAT3-mediated Survival and Invasion of Osteosarcoma Cells;Anticancer Research;2023-02-28